The Top 5 Biosimilars Articles for the Week of November 27

The Center for Biosimilars recaps the top 5 articles for the week of November 27.


Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of November 27.

Number 5: The World Health Organization has a released a new report that estimates that 1 in 10 drugs worldwide is either falsified or substandard, leading to unnecessary deaths and increased costs to patients and health systems.

Number 4: German drug maker Formycon projects that its biosimilar challenger to Lucentis will be launched in the US market in 2020.

Number 3: The FDA has begun to add 4-letter suffixes, devoid of meaning, to the nonproprietary names of newly approved biologics.

Number 2: Contributor Brian Lehman explains the potential impact of CMS’ proposed rule that would treat biosimilars as generic drugs for the purpose of cost-sharing under Medicare Part D.

Number 1: The FDA has approved Mylan and Biocon’s trastuzumab biosimilar, referenced on Herceptin.

Finally, last week, our e-newsletter asked whether you think that innovative device design will play a role in reference product sponsors’ defense strategies against biosimilar competition. To see results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit

Related Videos
Michael Kleinrock
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Ian Henshaw
Ian Henshaw
Ryan Haumschild, PharmD
John Gabrielson
Ryan Haumschild, PharmD, MS, MBA
Ryan Haumdschild, PharmD
Ryan Haumschild, PharmD
Related Content
© 2023 MJH Life Sciences

All rights reserved.